UT-MD Anderson Cancer Center: Pre-And Post-Surgical Immunotherapy Improves Outcomes for Patients With Operable Lung Cancer
May 17, 2024
May 17, 2024
HOUSTON, Texas, May 17 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone
* * *
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy - given before and after surgery - significant . . .
* * *
Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone
* * *
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy - given before and after surgery - significant . . .